SEC Form 4 · accession 0001140361-18-028123
Loxo Oncology, Inc. · LOXO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Keith T. Flaherty
Director
Period of report
Jun 7, 2018
Accepted (ET)
Jun 11, 2018 · 6:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001581720
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 7, 2018 | M | 50,000 | $1.184 | A | 59,732 | D | |
| Common StockF1,F2 | Jun 7, 2018 | S | 1,900 | $169.8458 | D | 57,832 | D | |
| Common StockF1,F3 | Jun 7, 2018 | S | 5,021 | $171.153 | D | 52,811 | D | |
| Common StockF1,F4 | Jun 7, 2018 | S | 4,634 | $172.0348 | D | 48,177 | D | |
| Common StockF1,F5 | Jun 7, 2018 | S | 12,243 | $173.322 | D | 35,934 | D | |
| Common StockF1,F6 | Jun 7, 2018 | S | 16,037 | $174.0446 | D | 19,897 | D | |
| Common StockF1,F7 | Jun 7, 2018 | S | 4,743 | $175.1004 | D | 15,154 | D | |
| Common StockF1,F8 | Jun 7, 2018 | S | 5,422 | $175.9712 | D | 9,732 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (right to buy)F9 | $1.184 | Jun 7, 2018 | M | 50,000 | D | — | Dec 16, 2023 | Common Stock | 50,000 | 32,345 | D |
Explanation of responses
- F1Represents the aggregate of sales effected on the same day at different prices.
- F2Represents the weighted average sales price per share. The shares sold at prices ranging from $169.44 to $170.11 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F3Represents the weighted average sales price per share. The shares sold at prices ranging from $170.55 to $171.48 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F4Represents the weighted average sales price per share. The shares sold at prices ranging from $171.57 to $172.56 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F5Represents the weighted average sales price per share. The shares sold at prices ranging from $172.60 to $173.585 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F6Represents the weighted average sales price per share. The shares sold at prices ranging from $173.60 to $174.545 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F7Represents the weighted average sales price per share. The shares sold at prices ranging from $174.61 to $175.595 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F8Represents the weighted average sales price per share. The shares sold at prices ranging from $175.63 to $176.59 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F9The stock option is immediately exercisable in full.